Cambridge Healthtech Institute’s 7th Annual
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Creating the Killer Combo
May 11-12, 2021
The development of bispecific antibodies is one of the most promising areas in biologics and their advancement to the clinic will be the final test of how these constructs behave in vivo. Investigators are working on novel approaches for activating
the immune response by targeting special cell populations. The 7th Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference brings together leading researchers in this area to strategize on the safety and efficacy of
new constructs, review the latest clinical results, and expand their use beyond oncology.
Coverage will include, but is not limited to:
- Explore strategies for the specific targeting of cell populations in tumors to minimize off target effects
- Review clinical and preclinical data
- Determine the best strategy for your application
- Balance toxicity and potency
- Expand scope of applications to infectious disease, CNS, transplantation and beyond
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is November 6, 2020.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Executive Director, Conferences and Fellow
For partnering and sponsorship information, please contact:
Senior Manager, Business Development
Manager, Business Development